Home > Pharmaceuticals > Europe

KOL Management and MSL Best Practice in Europe

2nd July to 3rd July 2012, Basel, Switzerland

Buy Now

Conference Buy Now Programme

Overview

Open/Close

SMi is proud to present their 4th annual KOL Europe Conference...

KOL Management and MSL Best Practice in Europe 2012

2nd & 3rd July 2012, Basel, Switzerland

About the Conference: SMi's 4th Annual European KOL and MSL conference will provide attendees with an in depth view into the most effective methods and strategies for pharma to use when recruiting and managing KOLs for dispersing medical or scientific information to stakeholders and the public

Identifying and building relationships with key opinion leaders is an essential part of the development process and it is important that the challenges in this field are addressed and solutions found. The event will explore KOL Communication strategies, KOLs in Market Access, Health Economics, MSL Evaluations, and Relationships with Patients and Government Bodies

This event will be focused on case-studies to add context to the presentations and will act as the perfect platform for discussion and problem-solving debate. Allowing for plenty of discussion within the agenda this conference is unique in providing an ideal platform to obtain the building blocks needed for successful KOL interactions and MSL programmes, whilst offering networking opportunities throughout the event.

Testimonials from delegates of our 2011 event:
"Excellent speaker and content" Boehringer-Ingelheim
"Good & new information, well presented & discussed" UCB
"Really good presenter & relevant information" ABPI

Interested in speaking at the conference; Do you know of anyone who may be interested in speaking; We are always on the look-out for new speakers for our upcoming conferences; Let us know - contact the the Conference Producer

For sponsorship and exhibiting opportunities, contact our Sponsorship Department

Key Benefits of Attending:

Hear from some of the leading experts in identifying, approaching and managing KOLs and KOL programmes

Learn the how to improve and sustain relationships with Patients and Government Bodies

Discover the best ways to manage the your medical and scientific advice output in the long term for the benefit of your brand

Network with MSLs, KOLs, industry leaders and medical communication agencies

Benefits of Attending

Open/Close

Featured Speakers

Open/Close

Who Should Attend

Open/Close

Buy Now

Conference Documentation

Qty.	Details
	Single User License	£499
	Site License	£1497

Programme

Expand all Timeslots

Collapse all Timeslots

8.30		Registration & Coffee
9.00		Chairman's Opening Remarks
9.10		Ensuring regulatory compliance when approaching the outside world Mario Monella, Director of Medical Affairs, Astellas Pharma Europe Ltd View Bio Industry trends in MSL compliance Common issues and uncertainties related to privacy Structure and strategies for ensuring global compliance Following regulatory guidelines and documentation
9.50		Cross-Regional KOL management Eddy Wu, Medical Director, Novartis Pharmaceuticals View Bio Maximize invested resources Define “good” standard, and make it “better” Enhance country-country cooperation
10.30		Morning Coffee
11.00		MSL in Orphan Disease: Hand-in-hand with a targeted sales force Andreas Brecht, Medical Scientific Liaison, Actelion Pharmaceuticals View Bio
11.40		New developments and relationships in continuing medical education (CME) Tom Pulles, International Medical Director, Shire AG View Bio What are the current challenges and changes in the CME landscape? Is it possible to bring multiple stakeholder groups together to develop education programmes in Europe? What is the role of the medical society in (European) CME? Can CME actually have an effect on clinical practice? What are the concerns about commercial organisations being involved in (accredited) CME meetings?
12.20		Networking Lunch
13.50		Developing MSL best practice strategies David Gillen, Medical Director , Celgene Europe Limited View Bio
14.30		Panel Discussion - How important are KOLs to the Pharma industry and how best can we manage them? Identifying a KOL - the first crucial step The importance of compliancy and transparency How and where can KOLs have the biggest impacts Novel utilities of KOL relationships
15.20		Afternoon Tea
15.50		KOL management in developing countries Stephen Toovey, Medical Consultant, Virology, Roche Pharmaceuticals View Bio Policital and security issues The importance of securing data transfer Embracing new technology in your communication strategy Making the most of the KOL in this situation
16.30		Chairman’s Closing Remarks and Close of Day One

8.30		Registration & Coffee
9.00		Chairman's Opening Remarks Dirk Roosen, Managing Director, R&S Management Consultancy View Bio
9.10		The role of patient and physician associations Susanna Palkonen, Executive Officer, EFA View Bio New legislation and how this will effect KOL relations Physicians backing away from industry relations Will Patient Opinion Leaders (POLs) replace KOLs How to get these groups on board How do patient organisations feel about engaging
9.40		Getting the most from Patient Association partnerships Keith Allan, Director, Global Advocacy, Novartis Pharma Ag View Bio • The potential influence of patient advocates • Understanding the principles of partnership • What patient associations want from industry • Rules of engagement
10.10		Q & A: Opportunities and Challenges of Patient Association Relations Keith Allan, Director, Global Advocacy, Novartis Pharma Ag View Bio Susanna Palkonen, Executive Officer, EFA View Bio
10.30		Morning Coffee
11.00		Types of initiatives involving both KOLs and Patient Groups Nick Hicks, Founder, Commutateur View Bio What dictates a successful outcome What Patient Groups are saying EULAR recommendations on working with Patient Groups in research Best practice case histories
11.40		Building and sustaining industry-academia relationships Thomas D. Szucs, Chairman, European Centre of Pharmaceutical Medicine (ECPM) View Bio Identifying the correct partner - what to look for and where to find it? Utilising these relationships to their full potential The importance of maintaining long term relationships - how can we do this? How and when should these partnerships end?
12.20		Networking Lunch
13.50		Improving effectiveness of MSLs Sven Erickson, Medical Science Liaison - Opthalmics, Novartis Sverige AB View Bio Performance metrics and management How can communication and transparency improve MSL activity Methods to increase scientific information exchange Overcoming obstacles in information sharing
14.30		Evaluating MSL value Dirk Roosen, Managing Director, R&S Management Consultancy View Bio MSL activity Allocation of resources to MSL activities Different activty ratios for organisations Challenges for MSL managers
15.10		Afternoon Tea
15.40		KOLs, physicians and new media Thierry Weber, MD, Partner, Vivactis View Bio Update on E-medical education Integration of KOLs in e-Learning and e-Meded - spreading the word to peers and physicians E-tools and science: update on online registries and studies E-marketing benefits of e-communication in the healthcare sector Help your KOLs gain visibility by capitalizing on new media (web and mobile media)
16.20		The internet, social media and mobile Daniel Ghinn, CEO, Creation Healthcare View Bio How emerging channels are changing healthcare engagement Focus on how pharma's stakeholder communicate Influencing other KOLs using emerging channels What does this mean for the pharma industry?
17.00		Chairman’s Closing Remarks and Close of Day Two Dirk Roosen, Managing Director, R&S Management Consultancy View Bio